Why Tempus AI Stock Was Motoring Higher This Week

Key Points

• A subsidiary announced an update to its cancer risk assessment platform.

• It said this enhances the system's ability to detect breast cancer.

• 10 stocks we like better than Tempus AI ›

What a difference a week can make on the stock market. Next-generation healthcare tech company Tempus AI's (NASDAQ: TEM) stock was doing quite well, thank you very much, over the past few days, in contrast to the preceding five-day trading stretch.

Due to some positive news from a subsidiary brought into its portfolio recently, this week to date (as of early Friday morning) Tempus AI's shares were rising by almost 14%, according to data compiled by S&P Global Market Intelligence.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Image source: Getty Images.

A technological leap forward

That subsidiary, California-based genetic testing specialist Ambry Genetics, was acquired by Tempus AI in February. Ambry announced a major upgrade to its cancer risk assessment platform Wednesday. It said that the Ambry CARE Program integrates data such as breast density to feed into the score calculated by the benchmark Tyrer-Cuzick breast cancer risk assessment tool.

This update, the company said, supplies "clinicians with more precise and personalized risk estimates at the point of care that can guide recommendations for breast cancer screening and risk reduction."

Ambry added that this type of cancer is the most common to be diagnosed in women. As such, it makes CARE that much more compelling for this large addressable market.

Reputation enhancer

Not only is this a boost for the Ambry Genetics product, it should also help burnish the reputation of Tempus AI as a whole. After all, the company has positioned itself as a cutting-edge, tech-forward solutions provider harnessing artificial intelligence (AI) to improve outcomes for patients.

Should you invest $1,000 in Tempus AI right now?

Before you buy stock in Tempus AI, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus AI wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $631,456!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,147,755!*

Now, it’s worth noting Stock Advisor’s total average return is 1,063% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of September 29, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.